These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 1672158)

  • 1. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
    Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
    J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.
    Högberg T; de Paulis T; Johansson L; Kumar Y; Hall H; Ogren SO
    J Med Chem; 1990 Aug; 33(8):2305-9. PubMed ID: 1973734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
    Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
    Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds.
    Högberg T; Bengtsson S; de Paulis T; Johansson L; Ström P; Hall H; Ogren SO
    J Med Chem; 1990 Apr; 33(4):1155-63. PubMed ID: 1969484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidopaminergic effects of the stereoisomers of N-[(1-alkyl-2- pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides.
    Murakami S; Marubayashi N; Fukuda T; Takehara S; Tahara T
    J Med Chem; 1991 Jan; 34(1):261-7. PubMed ID: 1825115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides.
    de Paulis T; Kumar Y; Johansson L; Rämsby S; Hall H; Sällemark M; Angeby-Möller K; Ogren SO
    J Med Chem; 1986 Jan; 29(1):61-9. PubMed ID: 3941414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides.
    de Paulis T; Kumar Y; Johansson L; Rämsby S; Florvall L; Hall H; Angeby-Möller K; Ogren SO
    J Med Chem; 1985 Sep; 28(9):1263-9. PubMed ID: 4040977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
    Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
    Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors.
    Bishop JE; Mathis CA; Gerdes JM; Whitney JM; Eaton AM; Mailman RB
    J Med Chem; 1991 May; 34(5):1612-24. PubMed ID: 1827843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
    Terai M; Hidaka K; Nakamura Y
    Eur J Pharmacol; 1989 Dec; 173(2-3):177-82. PubMed ID: 2576228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of high affinity, aryl-substituted [18F]fluoropropylbenzamides for dopamine D-2 receptor studies.
    Mathis CA; Bishop JE; Gerdes JM; Whitney JM; Brennan KM; Jagust WJ
    Int J Rad Appl Instrum B; 1992 Jul; 19(5):571-88. PubMed ID: 1399687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of dopamine D2-receptor selective antagonists.
    Högberg T
    Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
    Kung HF; Kasliwal R; Pan SG; Kung MP; Mach RH; Guo YZ
    J Med Chem; 1988 May; 31(5):1039-43. PubMed ID: 2966245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
    Malmberg A; Jerning E; Mohell N
    Eur J Pharmacol; 1996 May; 303(1-2):123-8. PubMed ID: 8804920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
    Köhler C; Karlsson-Boethius G
    J Neural Transm; 1988; 73(2):87-100. PubMed ID: 2974879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro binding profile and biodistribution of a 125I-labeled N-benzyl pyrrolidinyl benzamide derivative: a potential radioligand for mapping dopamine D2 receptors.
    Saji H; Tanahashi K; Kinoshita T; Iida Y; Magata Y; Yokoyama A
    Nucl Med Biol; 1996 Feb; 23(2):121-7. PubMed ID: 8868283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A; Gustafsson K; Andersson I
    Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
    Hall H; Wedel I
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
    Florijn WJ; Tarazi FI; Creese I
    J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.